Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy.
OBJECTIVE
To examine the clinical, genetic, and neuropathologic features of posterior cortical atrophy (PCA).


METHODS
Using a broad definition of PCA as a syndrome with the insidious onset of visual dysfunction in the absence of primary ophthalmologic causes, the authors identified and then reviewed the presenting signs and symptoms, ApoE genotypes, tau haplotypes, and neuropathologic findings when available of PCA cases from two dementia research centers collected over the past 14 years.


RESULTS
The authors identified 40 PCA cases. Their mean age at symptom onset was 60.5 +/- 8.9 years. There were twice as many women as men in the series. The principal types of visual impairment were simultanagnosia (82%) and visual field defect (47.5%). Acalculia, alexia, and anomia were also common. Insight was preserved in almost all (95%) early in the disorder. Neither apoE epsilon4 nor tau haplotype frequencies were different from typical Alzheimer disease (AD). Nine patients had died and underwent postmortem examination. Seven autopsied cases had AD pathology but when compared to typical AD, the neurofibrillary tangle (NFT) densities were significantly higher in Brodmann areas 17 and 18 (p < 0.05) and significantly lower in the hippocampus (p < 0.05). Two cases had corticobasal degeneration with maximal involvement of tau positive glial pathology in the posterior parietal lobe and Brodmann areas 17 and 18.


CONCLUSIONS
PCA is a distinctive dementia syndrome in which the most pronounced pathologic involvement is in the occipitoparietal regions independent of the specific underlying pathology. AD was the most common pathologic cause, but its regional distribution differed from typical AD.
Department of Neurology, Mayo Alzheimer's Disease Research Center, Rochester, MN, USA. david.tang-wai@uhn.on.ca
D F
DF
Tang-Wai
N R
NR
Graff-Radford
B F
BF
Boeve
D W
DW
Dickson
J E
JE
Parisi
R
R
Crook
R J
RJ
Caselli
D S
DS
Knopman
R C
RC
Petersen
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001057:Apolipoproteins E / Q000235:genetics; D001284:Atrophy / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D001344:Autopsy; D001921:Brain / Q000473:pathology; D002540:Cerebral Cortex / Q000473:pathology* / Q000503:physiopathology; D003704:Dementia / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D019636:Neurodegenerative Diseases / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D010468:Perceptual Disorders / Q000503:physiopathology; D014796:Visual Perception / Q000502:physiology; D016875:tau Proteins / Q000235:genetics
D001057:Apolipoproteins E; D016875:tau Proteins